12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Gainers

• Delcath Systems DCTH stock increased by 91.7% to $5.98 during Tuesday's pre-market session. The company's market cap stands at $91.3 million. As per the news, the Q2 earnings report came out 4 days ago.
• Tiziana Life Sciences TLSA stock increased by 46.5% to $0.88. The market value of their outstanding shares is at $88.7 million.
• G Medical Innovations GMVD shares increased by 45.79% to $0.27. The company's market cap stands at $2.6 million.
• SCYNEXIS SCYX stock rose 19.64% to $3.35. The company's market cap stands at $122.3 million. As per the news, the Q2 earnings report came out yesterday.
• Taysha Gene Therapies TSHA shares moved upwards by 15.96% to $2.47. The market value of their outstanding shares is at $158.5 million. As per the news, the Q2 earnings report came out yesterday.
• Evoke Pharma EVOK stock moved upwards by 15.44% to $1.57. The company's market cap stands at $5.2 million. The company's, Q2 earnings came out 3 days ago.

Losers

• Galecto GLTO shares declined by 65.8% to $0.8 during Tuesday's pre-market session. The market value of their outstanding shares is at $21.6 million.
• Design Therapeutics DSGN stock decreased by 54.98% to $3.3. The company's market cap stands at $184.6 million. As per the press release, Q2 earnings came out yesterday.
• Alaunos Therapeutics TCRT stock declined by 50.72% to $0.19. The market value of their outstanding shares is at $46.6 million. The company's, Q2 earnings came out yesterday.
• OptimizeRx OPRX stock decreased by 24.43% to $9.5. The market value of their outstanding shares is at $162.7 million. The company's, Q2 earnings came out yesterday.
• TFF Pharmaceuticals TFFP shares declined by 20.01% to $0.36. The company's market cap stands at $13.0 million. The company's, Q2 earnings came out yesterday.
• PHAXIAM Therapeutics PHXM stock fell 18.45% to $0.49. The market value of their outstanding shares is at $29.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.